Halozyme Therapeutics, Inc.

Merck & Co. is awaiting regulatory approvals for its subcutaneous version of PD-1 inhibitor pembrolizumab, and its successful head-to-head trial against the original intravenous Keytruda (pembroli

The US Food and Drug Administration’s newly revised stand on testosterone labeling for cardiovascular risk is the visible tip of the metaphorical iceberg of years of effort that went into evaluating a

Pfizer is pushing ahead with its effort to jump back into immune checkpoint inhibitor therapy with new Phase III results showing efficacy for its subcutaneous PD-1 inhibitor sasanlimab in non-muscle i

Bristol Myers Squibb’s Opdivo Qvantig, the new subcutaneous version of its PD-1 inhibitor Opdivo (nivolumab), will be available starting in early January with a list price that is at parity with the o